48 ANTI-AGEING


Treatment 1 @ Test Site


Tape Strip


Treatment Schedule


@ Home, Evening Treatment 2


Treatment 3 @ Test Site


@ Home, Evening Treatment 4


Treatment 5 @ Test Site


@ Home, Evening Treatment 6


Measurement Schedule


Treatment, TEWL, Chromameter & Photograph


1hr Post


(T0)


Treatment 2, TEWL, Chromameter & Photograph


12hr Post


(T2)


Treatment 4, TEWL, Chromameter & Photograph


Total Testing Time Frame 60 Hrs


Figure 8: Clinical barrier disruption protocol.


of the mouth. We were interested in looking at the ability of the mixture of polysaccharides to possibly extend skin hydration out past an 8-hour time frame. However, there are few published methods for running such studies. We elected, therefore, to develop a new procedure to examine extended skin hydration. This is outlined in Figure 12.10


The study parameters


examined a single application of the same two formulations noted above for the barrier recovery studies on ten [N=10] volunteers. During the extended treatment period the participants were asked to simply shower in the morning using only warm water on their arms, without soap. Following this procedure, we measured skin hydration using a DermaLab corneometer [Cortex Technology, Hadsund, Denmark]. The results of this initial study are shown


in Figure 13. As can be noted, the formulation containing 3% of the polysaccharides begins showing statistically superior skin hydration after the second hour of application and this remains significant out


35 30 25 20 15 10 5 0


Control Placebo ***


to the 8th hour. However, upon return at hour 24 and hour 48, only the formulation containing the 3% polysaccharides continues to show statistically significant skin hydrating effects. The formulation without the polysaccharides fails to maintain statistically significant moisturisation benefits. Following the study noted above, a similar study was undertaken to look at what would happen if we simply added 3% of the polysaccharides directly to a well-known commercial skin moisturiser. This commercial formulation contains a significant amount of glycerin (likely over 8%) and sodium hyaluronate as the key moisturisers in the formulation and is suggested to provide deep skin moisturising benefits. We followed the exact same procedure as noted above for the original study. In this study, we employed six [N=6] individuals again testing the formulations on the inner volar forearm. As a placebo in this study, we employed the commercial formulation. Importantly, the addition of 3% of the polysaccharide blend occurred quickly with mixing and did not


N=10, p≤0.05


1.8 1.6 1.4 1.2 1


Active


Figure 9: Difference in TEWL measurements between the averaged T0 measurement and T5 measurement on 5 individuals tape stripped and treated with creams including: 3% Polysaccharide Blend (Active, B), Placebo (Placebo, A) and Untreated (Control) over the course of 60 Hours with treatments 2X/day. Asterisks indicate statistical significance (p≤0.05).


PERSONAL CARE EUROPE


0.8 0.6 0.4 0.2 0


Control Placebo Active Figure 10: Average change in skin Erythemal Index from T0 to T5. April 2020


change the overall appearance or rheology of the commercial formulation. The data from this study was also quite


interesting and can be seen in Figure 14. From this study, it was noted that both formulations showed very similar hydrating benefits out to 8 hours. However, moving to the 24th and 48th hours, the commercial formulation fell out of statistical significance versus the baseline measurement while the formulation containing the 3% polysaccharide blend did not. From these testing results, we have proposed a hypothesis that, to maintain extended skin hydration, it is necessary to apply ingredients on the skin that are not low molecular weight molecules like sodium PCA, glycerin, urea or lactic acid.10


Instead,


to effectively maintain extended skin moisturisation, it may be necessary to apply higher molecular weight, polymeric ingredients, preferably natural, that bond to water very well, but that the skin does not recognise naturally and cannot rapidly remove via the normal skin biological


N=10, p≤0.3


12hr Post


(T4)


Treatment 5, TEWL, Chromameter & Photograph


12hr Post


(T5)


36%


TEWL (g/m2


/hr) Avg ∆ (T0-T5)


Erythemal Index (Avg ∆ (T0-T5)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140  |  Page 141  |  Page 142  |  Page 143  |  Page 144  |  Page 145  |  Page 146  |  Page 147  |  Page 148  |  Page 149  |  Page 150  |  Page 151  |  Page 152  |  Page 153  |  Page 154  |  Page 155  |  Page 156  |  Page 157  |  Page 158  |  Page 159  |  Page 160  |  Page 161  |  Page 162  |  Page 163  |  Page 164  |  Page 165  |  Page 166  |  Page 167  |  Page 168  |  Page 169  |  Page 170  |  Page 171  |  Page 172  |  Page 173  |  Page 174  |  Page 175  |  Page 176  |  Page 177  |  Page 178  |  Page 179  |  Page 180  |  Page 181  |  Page 182  |  Page 183  |  Page 184  |  Page 185  |  Page 186  |  Page 187  |  Page 188  |  Page 189  |  Page 190  |  Page 191  |  Page 192  |  Page 193  |  Page 194  |  Page 195  |  Page 196